VYSNOVA SIGNS TWO-YEAR CONTRACT WITH THE U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION FOR IMPLEMENTING A COVID-19 COMMUNITY RESEARCH PARTNERSHIP

Landover, MD – July 15, 2020 – Vysnova Partners Inc., in association with Wake Forest Baptist Health and other premier health systems and corporations, has received an over $54 million, two-year contract from the U.S. Centers for Disease Control and Prevention (CDC) to coordinate research on the COVID-19 public health emergency in the United States.

The goal of the prospective study is to address key epidemiological and clinical questions about the disease by undertaking a multi-site study of COVID-19 in patients and healthcare workers at participating health systems in the Southeastern and Mid-Atlantic regions of the country.

The study will provide urgently needed estimates of the population prevalence and incidence of COVID-19 and will examine the geographic, demographic and chronologic distributions, as well as clinical consequences.

“Our team hopes to develop a more complete understanding of the disease by determining the frequency of infection, learning how it is transmitted and pinpointing who gets infected to help plan public health interventions,” said Carlos Rivera, CEO and President of Vysnova Partners Inc., a leading program management firm located in Landover, Md.

Wake Forest Baptist Health, based in Winston-Salem, N.C., will serve as the lead investigative institution for the study, responsible for scientific oversight and direction.

The George Washington University’s Biostatistics Center will serve as the data coordinating center to analyze the information collected.

The other institutions participating in the study are Atrium Health, MedStar Health, the University of Maryland Medical System, University of Mississippi Medical Center, Tulane University School of Public Health and Tropical Medicine, Oracle Corp., Neoteryx, Scanwell Health, Javara Inc., LabCorp and United Parcel Service.

Over the course of the study, participants will report daily exposures, risk-reduction behaviors and respiratory disease symptoms through a secure app on their smartphone, tablet or computer.  In addition, a systematic sample of participants will receive at-home test kits to identify levels of COVID-19 antibodies. Electronic health record data will be accessed to complement participant self-reported data. Additionally, the effectiveness of some personal protective equipment will be analyzed among health care workers.

“Wake Forest Baptist is honored to be part of this critical effort to study the disease and to make a contribution to what is potentially one of the critical epidemics in the world since the 1918 flu pandemic,” said the principal investigator of the study Thomas Wierzba, Ph.D., professor of infectious diseases at Wake Forest Baptist.

 

Original post https://alertarticles.info